We investigate high-frequency reactions in the Eurozone stock market and the UK stock market during the time period surrounding European Central Bank (ECB) and the Bank of England (BoE)'s interest rate decisions, assessing how these two markets react and co-move influencing each other. The effects are quantified by measuring linear and nonlinear transfer entropy combined with a bivariate empirical mode decomposition from a dataset of 1 min prices for the Euro Stoxx 50 and the FTSE 100 stock indices. We uncover that central banks' interest rate decisions induce an upsurge in intraday volatility that is more pronounced on ECB announcement days and there is a significant information flow between the markets with prevalent direction going from the market where the announcement is made towards the other.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965417 | PMC |
| http://dx.doi.org/10.1098/rsos.211342 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The history of the Croatian pharmaceutical company PLIVA from the very beginning to the status of a recognisable European and global player is described. Special attention is paid to PLIVA's cooperation with the Croatian Nobel laureate Vladimir Prelog and the invention of the proprietary antibiotic azithromycin. The antibiotic was commercialised in cooperation with the US-based company Pfizer.
View Article and Find Full Text PDFEvaluating the Impact of Private and Public Sentiments on the Linkage Between Gold and Stock Markets: Evidence from China.
Eval Rev
January 2025
School of Finance, Yunnan University of Finance and Economics, Kunming, China.
Gold and stocks, which are conventionally regarded as a safe haven and risk assets, respectively, exhibit complex interrelationships, with significant implications for financial risk management. This paper builds on the sentiment categorization proposed by Liang et al. (2020) to distinguish between private and public sector sentiment.
View Article and Find Full Text PDFTreatment Patterns and Outcomes in Patients with Advanced Biliary Tract Cancers Treated with Gemcitabine-Based Chemotherapy: A Retrospective Study.
Cancers (Basel)
January 2025
Division of Medical Oncology, Mayo Clinic, Phoenix, AZ 85054, USA.
Historically, the standard of care for advanced biliary tract cancers (aBTCs) was gemcitabine plus cisplatin (GemCis). Immunotherapy plus GemCis is now recommended as a first-line treatment for aBTCs. Whether patients can tolerate eight cycles of GemCis in clinical practice, as per the Advanced Biliary Cancer (ABC)-02 study, remains to be assessed.
View Article and Find Full Text PDFHigh clinical burden of classical homocystinuria in the United States: a retrospective analysis.
Orphanet J Rare Dis
January 2025
Travere Therapeutics, Inc., San Diego, CA, USA.
Background: Classical homocystinuria (HCU) is a rare genetic metabolic disorder resulting in elevated homocysteine and methionine levels. The clinical characteristics and associated complications of HCU are well documented. However, there is limited published research on the clinical burden of patients with HCU, especially stratified by total homocysteine (tHcy) levels.
View Article and Find Full Text PDFPhysical climate risk: Stock price reactions to the historically most extreme European and United States heat waves since 1979.
PLoS One
January 2025
Institute of Management, Accounting and Finance, Leuphana University Lüneburg, Lüneburg, Lower Saxony, Germany.
Climate change has heightened the need to understand physical climate risks, such as the increasing frequency and severity of heat waves, for informed financial decision-making. This study investigates the financial implications of extreme heat waves on stock returns in Europe and the United States. Accordingly, the study combines meteorological and stock market data by integrating methodologies from both climate science and finance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!